Vivesto AB (VIVE.ST) stock: key figures, P/E, revenue and dividend
Health Care · Sweden · ISIN SE0000722365
Vivesto AB financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | – | 0.00 SEK |
| Operating income | – | -34.38 m SEK |
| Net income | – | -34.08 m SEK |
Full history since 2004, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was founded in 1988 and is headquartered in Solna, Sweden.
More stocks
- Global Dominion Access S.A (DOM.MC)
- United Faith Auto-Engineering Co. Ltd. (301112.SZ)
- ONE LIBERTY PROPERTIES INC (OLP)
- VALHI INC /DE/ (VHI)
- Magnera Corp (MAGN)
- SDCL Efficiency Income Trust PLC (SEIT.L)
- ZJBC Information Technology Co Ltd (000889.SZ)
- Shenyang Chemical Industry Co Ltd (000698.SZ)
- Surya Citra Media Tbk (SCMA.JK)
- Shenzhen Etmade Automatic Equipment (300812.SZ)
- ETHAN ALLEN INTERIORS INC (ETD)
- Wuxi Double Elephant Micro Fibre Material Co Ltd (002395.SZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.